Previous close | 11.60 |
Open | 11.90 |
Bid | 11.07 x 100 |
Ask | 11.19 x 100 |
Day's range | 10.81 - 11.99 |
52-week range | 6.50 - 14.74 |
Volume | |
Avg. volume | 112,424 |
Market cap | 219.94M |
Beta (5Y monthly) | 1.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.67 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.67 |
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer’s Disease (AD) for more than three years under the Australian compassionate use program known as the Special A
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce the successful completion of the first cohort in the trial. Foll
Potential INmune Bio, Inc. ( NASDAQ:INMB ) shareholders may wish to note that the Independent Director, Scott Juda...